Understanding how NADH levels affect fatty liver disease and cholesterol levels
An NADH-ChREBP axis in fatty liver disease and dyslipidemia
This study is looking at how high levels of a substance called NADH in the liver might lead to fatty liver disease and problems with cholesterol, and it's for anyone interested in understanding how these conditions develop and finding new ways to improve liver health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10989939 on NIH RePORTER |
What this research studies
This research investigates the role of elevated NADH levels in the liver and how they contribute to fatty liver disease and dyslipidemia. By studying both alcoholic and non-alcoholic fatty liver diseases, the researchers aim to uncover the metabolic mechanisms that lead to these conditions. They will utilize a novel metabolic tool to manipulate NADH levels in animal models, which will help clarify the relationship between NADH and fat accumulation in the liver. The ultimate goal is to identify new therapeutic strategies that target NADH to improve liver health and metabolic outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with alcoholic or non-alcoholic fatty liver disease.
Not a fit: Patients with liver diseases unrelated to fatty liver or those without metabolic disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for fatty liver disease and related metabolic disorders.
How similar studies have performed: Previous research has indicated that targeting metabolic pathways can lead to significant improvements in liver health, suggesting potential success for this approach.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Goodman, Russell Paul — Massachusetts General Hospital
- Study coordinator: Goodman, Russell Paul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.